혈액 기반 바이오마커 시장 보고서(2025년)
Blood Based Biomarkers Global Market Report 2025
상품코드 : 1760490
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈액 기반 바이오마커 시장 규모는 향후 몇 년 동안 12.4%의 연평균 성장률로 2029년까지 415억 5,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 바이오마커 분석에서 AI 및 머신러닝의 확대, 질병 조기 발견에 대한 수요 증가, 원격의료 및 원격 진단의 성장, 만성질환의 유병률 증가, 소비자의 건강 인식 증가에 의해 주도될 것으로 보입니다. 이 기간의 주요 동향으로는 AI를 활용한 바이오마커 탐색, 액체 생검의 발전, 멀티오믹스 통합, 현장진단(POC) 검사기기 개발, 차세대 염기서열분석(NGS) 혁신 등이 있습니다.

심혈관질환의 유병률 증가는 혈액 기반 바이오마커 시장의 성장을 촉진할 것으로 예상됩니다. 심혈관질환은 관상동맥질환, 심부전, 뇌졸중 등 심장과 혈관에 영향을 미치는 질환을 포함하며, 식습관 장애 및 비만율 증가와 같은 위험 요인으로 인해 더욱 보편화되고 있습니다. 혈액 기반 바이오마커는 혈액 내 측정 가능한 물질을 통해 질병의 진행, 위험 평가, 치료 반응에 대한 귀중한 정보를 제공함으로써 이러한 질병의 진단 및 모니터링에 중요한 역할을 하고 있습니다. 2024년 9월 국립생명공학정보센터(National Center for Biotechnology Information)가 실시한 세계 건강 조사 이니셔티브에 따르면 2025-2050년까지 심혈관 질환 환자가 90% 증가하고, 심혈관 질환으로 인한 사망자 수는 2050년까지 3,560만 명에 이를 것으로 예측하고 있습니다. 이러한 심혈관질환의 유병률 증가가 혈액 기반 바이오마커 시장의 성장에 기여하고 있습니다.

혈액 기반 바이오마커 시장의 주요 기업들은 알츠하이머병 등의 진단에 도움이 되는 고정밀 혈액 바이오마커 검사와 같은 기술 혁신에 집중하고 있습니다. 이러한 검사는 혈액 내 특정 바이오마커를 활용하여 높은 정확도와 신뢰성으로 건강 상태를 감지하거나 모니터링합니다. 예를 들어, 미국 생명과학 기업 퀀테릭스(Quanterix)는 2023년 10월, 의사가 인지기능 장애가 있는 성인의 알츠하이머병 진단을 돕기 위해 고안된 고정밀 혈액 바이오마커 검사인 LucentAD p-Tau 217 검사를 발표하였습니다. 이 검사는 알츠하이머병의 병태, 특히 뇌 내 아밀로이드 축적과 밀접한 연관이 있는 트레오닌 217로 인산화 된 타우 단백질(p-Tau 217)을 측정하는 검사로, 90% 이상의 정확도를 제공하며, 엄격한 진단 기준을 충족하는 검사입니다. 단독이 아닌 다른 진단 도구와 병행하여 사용하도록 되어 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Blood-based biomarkers are substances in the blood that can be measured to indicate the presence, progression, or response to a disease. They are primarily used for early detection, helping to personalize treatment plans and monitor treatment effectiveness with minimal invasiveness.

These biomarkers can be categorized into several types, including genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, which are based on DNA or RNA, identify genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. They are utilized in various advanced technologies, such as next-generation sequencing, polymerase chain reaction, immunoassays, and mass spectrometry. These biomarkers play a critical role in diagnosing and monitoring diseases such as cancer, cardiovascular conditions, neurological disorders, and immunological diseases. Key users of these biomarkers include hospitals, clinics, diagnostic labs, research institutes, and other healthcare providers.

The blood-based biomarkers market research report is one of a series of new reports from The Business Research Company that provides blood-based biomarkers market statistics, including the blood-based biomarkers industry global market size, regional shares, competitors with the blood-based biomarkers market share, detailed blood-based biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the blood-based biomarkers industry. This blood-based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The blood-based biomarkers market size has grown rapidly in recent years. It will grow from $23.13 billion in 2024 to $26.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth observed in the past can be attributed to the increasing global incidence of cancer, a higher adoption of personalized medicine, more funding in biomarker research, a rise in clinical trials involving biomarkers, and an increase in the approval of companion diagnostics.

The blood-based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period is expected to be driven by the expansion of AI and machine learning in biomarker analysis, a higher demand for early disease detection, the growth of telemedicine and remote diagnostics, the increasing prevalence of chronic diseases, and greater health awareness among consumers. Key trends during this period will include AI-driven biomarker discovery, advancements in liquid biopsy, integration of multi-omics, development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market. Cardiovascular diseases, which encompass disorders affecting the heart and blood vessels such as coronary artery disease, heart failure, and stroke, are becoming more common due to risk factors such as poor diet and rising obesity rates. Blood-based biomarkers play a crucial role in diagnosing and monitoring these diseases by offering valuable information on disease progression, risk assessment, and treatment response through measurable substances in the blood. A global health research initiative by the National Center for Biotechnology Information in September 2024 projected a 90% increase in cardiovascular disease cases from 2025 to 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. This rising incidence of cardiovascular diseases is contributing to the market growth for blood-based biomarkers.

Leading companies in the blood-based biomarkers market are focusing on technological innovations, such as high-accuracy blood biomarker tests, to assist in diagnosing diseases such as Alzheimer's disease. These tests use specific biomarkers in the blood to detect or monitor health conditions with high precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, introduced the LucentAD p-Tau 217 test, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer's disease in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), which is strongly linked to Alzheimer's pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test provides over 90% accuracy, fulfilling stringent diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than independently.

In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. This acquisition allows Danaher to enhance its life sciences portfolio by incorporating Abcam's leading protein consumables and research tools. Abcam, a UK-based life sciences company, specializes in the development and distribution of research tools, including antibodies, assays, and reagents.

Major players in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blood-based biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blood-based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Based Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blood based biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for blood based biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood based biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Blood Based Biomarkers Market Characteristics

3. Blood Based Biomarkers Market Trends And Strategies

4. Blood Based Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Blood Based Biomarkers Growth Analysis And Strategic Analysis Framework

6. Blood Based Biomarkers Market Segmentation

7. Blood Based Biomarkers Market Regional And Country Analysis

8. Asia-Pacific Blood Based Biomarkers Market

9. China Blood Based Biomarkers Market

10. India Blood Based Biomarkers Market

11. Japan Blood Based Biomarkers Market

12. Australia Blood Based Biomarkers Market

13. Indonesia Blood Based Biomarkers Market

14. South Korea Blood Based Biomarkers Market

15. Western Europe Blood Based Biomarkers Market

16. UK Blood Based Biomarkers Market

17. Germany Blood Based Biomarkers Market

18. France Blood Based Biomarkers Market

19. Italy Blood Based Biomarkers Market

20. Spain Blood Based Biomarkers Market

21. Eastern Europe Blood Based Biomarkers Market

22. Russia Blood Based Biomarkers Market

23. North America Blood Based Biomarkers Market

24. USA Blood Based Biomarkers Market

25. Canada Blood Based Biomarkers Market

26. South America Blood Based Biomarkers Market

27. Brazil Blood Based Biomarkers Market

28. Middle East Blood Based Biomarkers Market

29. Africa Blood Based Biomarkers Market

30. Blood Based Biomarkers Market Competitive Landscape And Company Profiles

31. Blood Based Biomarkers Market Other Major And Innovative Companies

32. Global Blood Based Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blood Based Biomarkers Market

34. Recent Developments In The Blood Based Biomarkers Market

35. Blood Based Biomarkers Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기